Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
ASX gold miner under pressure to sell by activist investor
stocks
Ask the Analyst: Will Amcor lose its dividend aristocrat status?
stocks
Chart of the Week: We see opportunity in this beaten down industrial player
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.10 | 69.40 | -0.77% |
| CAC 40 | 8,150.42 | 58.67 | -0.71% |
| DAX 40 | 24,795.94 | 328.23 | -1.31% |
| Dow JONES (US) | 50,687.07 | 620.72 | -1.21% |
| FTSE 100 | 10,332.30 | 41.21 | -0.40% |
| HKSE | 25,257.64 | 375.57 | -1.47% |
| NASDAQ | 26,853.98 | 239.92 | -0.89% |
| Nikkei 225 | 67,274.05 | 1,128.09 | -1.65% |
| NZX 50 Index | 13,070.18 | 44.90 | -0.34% |
| S&P 500 | 7,553.68 | 56.10 | -0.74% |
| S&P/ASX 200 | 8,674.80 | 70.80 | -0.81% |
| SSE Composite Index | 4,066.56 | 17.42 | -0.43% |